Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in patients with acute exacerbation of chronic bronchitis or mild community-acquired pneumonia.

This postmarketing observational study is non-interventional and is being conducted in a prospective, single-arm, single-country, multicenter format.

Klacid SR will be prescribed in usual manner in accordance with the terms of the local market authorization with regards to dose, population, and indication as well as with local guidelines.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Clarithromycin

Criteria

Inclusion Criteria:

• Men, women 18 years with

1. Acute tracheitis.

2. Acute tracheobronchitis.

3. Acute bronchitis.

4. Mild community-acquired pneumonia.

5. Acute exacerbation of chronic bronchitis.

• To whom decision to initiate Klacid SR therapy in a dose of 1000 mg has been made by physician.

Exclusion Criteria:

• Known hypersensitivity to macrolide antibiotics

• Documented renal impairment (creatinine clearance under 30 ml/min)

• Concomitant therapy with the following drugs: astemizole, cisapride, pimozide, terfenadine and ergotamine or dihydroergotamine

• Pregnancy

• Breast feeding